Delivering timely service and evidence-informed resources to people in BC and the Yukon facing cancer and those involved in oncology care or research.
The IARC Monographs identify environmental factors that are carcinogenic hazards to humans. These include chemicals, complex mixtures, occupational exposures, physical agents, biological agents, and lifestyle factors. National health agencies can use this information as scientific support for their…
The IARC Monographs identify environmental factors that are carcinogenic hazards to humans. These include chemicals, complex mixtures, occupational exposures, physical agents, biological agents, and lifestyle factors. National health agencies can use this information as scientific support for their…
The IARC Monographs identify environmental factors that are carcinogenic hazards to humans. These include chemicals, complex mixtures, occupational exposures, physical agents, biological agents, and lifestyle factors. National health agencies can use this information as scientific support for their…
The IARC Monographs identify environmental factors that are carcinogenic hazards to humans. These include chemicals, complex mixtures, occupational exposures, physical agents, biological agents, and lifestyle factors. National health agencies can use this information as scientific support for their…
This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 2-9 June 2015
This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 2-9 February 2016
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
Table of Contents:; 1. Immunotherapy administration; 2. Immunotherapy; 3. Cancer immunotherapy; 4. CAR T-cell therapy; 5. Cytokine release syndrome; 6. Developming infrastructure; 7. Immunotherapy toxicities; 8. Checkpoint inhibitors; 9. Toxicity managment; 10.Oncolytic viruses
c.1 BC Cancer Agency VAN Library | Available | ||
c.2 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency KEL Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
BC Cancer Agency VAN Library | Available |